Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Provided By GlobeNewswire
Last update: Feb 14, 2025
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025-
-Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025-
Read more at globenewswire.comNASDAQ:BNTC (7/22/2025, 10:45:34 AM)
11.32
+0.14 (+1.25%)
Find more stocks in the Stock Screener
